RxDoctor Payments Data

Maday Campo-Hernandez, PA

Medical · Altamonte Springs, FLNPI 1205566833

Payments from drug & device makers

$650in general payments, 2019–2025

Across 28 payments — averaging $23.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$174
  • Novo Nordisk$146
  • Lilly USA, LLC$85
  • AbbVie$52
  • Pfizer$47
  • GSK$34
  • plus $112 from 5 others

What the payments were for

  • Food & beverage$650100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$650 in reported general payments places this provider in the 45th percentile of 2,031 medical providers in Florida.

See all medical providers in Florida

Medicare billing

Part B allowed, 2024
$3,698
Medicare patients
35
Services billed
95

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide44$46,819
JardianceEmpagliflozin25$30,918
OzempicSemaglutide19$26,911
EliquisApixaban26$21,578
FarxigaDapagliflozin Propanediol14$21,457
RybelsusSemaglutide11$15,729
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$14,362
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$2,641
Albuterol Sulfate HfaAlbuterol Sulfate38$1,581
Rosuvastatin Calcium94$983
Levothyroxine Sodium83$690
Atorvastatin Calcium77$641
Trazodone Hcl18$639
Potassium Chloride22$458
Gabapentin32$448

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$85$46,81944 claims
Novo NordiskOzempic, Rybelsus$146$42,64030 claims
Boehringer IngelheimJardiance$28$30,91825 claims
PfizerEliquis$47$21,57826 claims
AstraZenecaFarxiga$174$21,45714 claims
GSKTrelegy Ellipta$34$14,36221 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$17$69083 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 2,031 medical providers in Florida.

Other medical in Altamonte Springs

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →